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Hypoxia-inducible factor-1aAbstract Neural stem cell (NSC) transplantation is an effective method of giving a supplement of
cells lost and promoting functional recovery after spinal cord injury (SCI). Nonetheless, owing to
hostile environments at the injury site, such as ischaemic hypoxia conditions and inﬂammatory
cytokines, poor cell survival and uncontrolled differentiation are consistent problems encountered
following NSC transplantation in ischaemic neural tissue. Hypoxia-inducible factor-1a (HIF-1a)
provides profound protection to NSCs against negative factors at the injury site. On the other hand,
HIF-1 can induce NSCs to differentiate into neurons. We predict that transplanted NSCs modiﬁed
by an HIF-1a gene would have a better efﬁcacy for promoting neural regeneration and functional
reconstruction.
Crown Copyright ª 2013 Tehran University of Medical Sciences. Published by Elsevier Ltd.
Open access under CC BY-NC-ND license.Introduction
Spinal cord injury (SCI) is a kind of disabling condition of
the central nervous system that leads to a heavy burden on
family and society. Cellular therapy provides a method of
giving a supplement of cells lost in the injury and promoting
functional recovery after SCI. The rationales for thisapproach can be summarised as follows: (a) to promote the
functional reconstruction of neuronal circuits, (b) to exhibit
trophic effects and (c) to simulate the remyelination of
axons [1]. However, owing to a hostile environment at the
injury site, such as ischaemic hypoxia conditions and inﬂam-
matory cytokines, poor cell survival and uncontrolled differ-
entiation are consistent problems encountered followingublic of
Y-NC-ND license.
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tissue [2–5].
Hypothesis/idea
In order to improve the survival of transplanted NSCs, en-
hance angiogenesis in the injured site and promote differentia-
tion of neurons, we proposed a conjecture: to introduce the
hypoxia-inducible factor-1a (HIF-1a) expression system into
the NSCs so as to establish a controlled HIF-1a-expressing
stable NSC line. Accordingly, transplantation with HIF-1a-
expressing NSCs can effectively solve the above-mentioned
problems.Evaluation of the hypothesis/idea
HIF-1 is a transcriptional regulator of oxygen homeostasis
and a key factor for generating the adaptive responses
through upregulation of various target genes involved in
erythropoiesis, angiogenesis, vascular tone maintenance,
mitochondrial function, cell survival following ischaemic/
hypoxic injury as well as glucose metabolism and transport.
The regulation of the HIF-1 activity depends mostly upon
the alpha subunit. The triggered expression of HIF-1a pro-
vides profound protection against focal cerebral ischaemia
[6–8]. The HIF-1a downregulated the genes responsible for
protection in ischaemic hypoxia injury, such as erythropoietin
(EPO), vascular endothelial growth factor (VEGF), vascular
tone, glycolytic enzymes and so on [9–17]. Potentially intrin-
sic mechanisms: (a) promote endothelial cell proliferation and
blood vessel formation, (b) have a direct protective effect on
nerve tissue [18,19], (c) tolerate against excitotoxicity of nerve
cell [20] and (d) reduce tissue oedema and inﬂammatory reac-
tion by the activation of superoxide dismutase and glutathi-
one peroxidase [21,22].
Conditionally inactivating the hypoxia-responsive tran-
scription factor HIF-1a in murine can reduce NSC survival
and proliferation rate [23]. Upregulation of HIF-1a can pro-
mote NSC proliferation on the one hand and induce NSCs
to differentiate into neurons on the other [24,25]. HIF-1a
seems to be a transcription factor that is relevant to the devel-
opment and survival of neurons that are involved in HIF-1 sig-
nalling pathway activation and result in a downstream of a
variety of target gene upregulation. Furthermore, stem cell fac-
tor (SCF), a downstream target gene of HIF-1, can promote
neuronal differentiation and inhibit astroglial differentiation
at the early stage of NSC differentiation [26]. Some studies also
showed that VEGF plays a guiding role in axon growth
[27,28]. Meanwhile, the level of VEGF has an effect on the
migration of nerve cells [29].Discussion/conclusion
Compared with traditional NSC transplantation, the advanta-
ges of NSCs that are modiﬁed by HIF-1a gene transplantation
are as follows: (a) the cell survival rate of the transplanted
NSCs is higher in the negative environment at the injury site,
(b) local expression of HIF-1a increases angiogenesis after in-
jury and improves cell ability of anti-apoptosis in damaged tis-
sue and (c) the HIF-1a-expressing cells can be self-induced todifferentiate into neurons without extra help. In general, trans-
planted HIF-1a-expressing NSCs will bring a promising ther-
apy method for people afﬂicted with SCI.Overview box
First Question: What do we already know about the
subject?
Hypoxia-inducible factor-1 (HIF-1) is a transcriptional
regulator of oxygen homeostasis and a key factor in the
generation of the adaptive responses through upregula-
tion of various target genes involved in erythropoiesis,
angiogenesis, vascular tone maintenance, mitochondrial
function, cell survival following ischaemic/hypoxic injury
as well as glucose metabolism and transport. In addition,
upregulation of HIF-1a can promote neural stem cell
(NSC) proliferation on the one hand and induce NSCs
to differentiate into neurons on the other.
Second Question: What does your proposed theory add
to the current knowledge available, and what beneﬁts does
it have?
Compared with traditional NSC transplantation, the
advantages of NSCs that are modiﬁed by HIF-1a gene
transplantation are as follows: (a) the cell survival rate
of the transplanted NSCs is higher in the negative envi-
ronment at the injury site, (b) local expression of HIF-
1a increases angiogenesis after injury and improves cell
ability of anti-apoptosis in damaged tissue and (c) the
HIF-1a-expressing cells can be self-induced to differenti-
ate into neurons without extra help.
Third Question: Among numerous available studies,
what special further study is proposed for testing the idea?
How does one construct a recombinant defective retro-
viral vector carrying the HIF-1a gene and stable virus-
producing packaging NSCs, and then treat spinal cord
injury in a secure way?Conﬂict of interest
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